A Real-world Study of the Efficacy and Safety of ICIs as First-line Therapy for Advanced Malignancies

Recruiting now

Conditions studied: Malignant Tumor, Immunotherapy, Artificial Intelligence

In brief

In this study, we collected the data of immunohistochemistry, gene detection, image, OS, PFS, Orr, and so on. Secondly, the database of immunotherapy for malignant tumor was established, and the predictive model was constructed to verify and establish the rationality and validity of the biomarkers and predictive system of immunotherapy

Key facts

Study ID

NCT05862259

Run by

Xinqiao Hospital of Chongqing

People needed

120

Starts

2023-08-10

Expected to finish

2025-12-31

Last updated by the study team

2025-07-14

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Informed consent has been signed and, in the judgment of the investigator, the patient is able to comply with the study protocol and sign a written informed consent.
• the advanced malignant tumors (solid tumors of the non-small-cell lung carcinoma, stomach, breast, urinary system, etc.) were diagnosed by histopathology.
• the stage IV according to the eighth edition of IASLC.
• PS 0-2, the expected survival > 3 months.
• the age of 18-75 years.
• no contraindication to treatment with immune checkpoint inhibitors.

You may not qualify if…

• the patients' compliance was poor, which violated the rules of the trial;
• the patients with severe dysfunction of vital organs (heart, liver and kidney) ;
• the patients with other malignant tumors;
• the researchers considered that the patients should not participate in other conditions of the trial.

Where it is running

• the second affiliated hospital of Army medical university — Chongqing, Chongqing Municipality, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.